Xtampza ER, an Oxycodone Analgesic with Abuse-Deterrent Properties, Approved for the Treatment of Patients with Chronic Pain
Opioid analgesics are among the most often prescribed drug classes in the United States. The National Institute on Drug Abuse estimated that in 2014, US pharmacies dispensed 245 million prescriptions for opioids for the treatment of patients with acute or chronic pain.
Zinbryta (Daclizumab): First Once-Monthly, Self-Administered Treatment Approved for Patients with Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS) that causes demyelination and axonal damage in the brain, spinal cord, and optic nerves. The demyelination in MS is thought to be the result of abnormal immune response in which activated lymphocytes (T-cells and possibly B-cells) impact the CNS myelin.
On June 22, 2015, the US Food and Drug Administration (FDA) approved an expanded indication for perampanel hydrate (Fycompa; Eisai), an oral antiepileptic drug. This new indication allows the use of perampanel hydrate as an adjunctive treatment for primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy aged ≥12 years. The FDA approval was based on new data from a phase 3 clinical trial showing a significant reduction in the frequency of PGTC seizures and freedom from seizures with perampanel hydrate versus placebo.
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Higher Dose, Fewer Weekly Injections of Copaxone (Glatiramer Acetate) Approved by the FDA for Patients with Relapsing Forms of Multiple Sclerosis
Results 1 - 5 of 5